Hepatitis C Epidemiology: Insights from a Comprehensive Cohort Study in ASST Melegnano and Martesana, Lombardia Region, Northern Italy
Pathogens · 2024
DOI: 10.3390/pathogens13030215 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Pathogens, 2024. Verfasst von Michele Nardone und 11 weiteren Autor:innen. Beteiligte Einrichtung: Azienda Socio-Sanitaria Territoriale Melegnano Martesana, Regione Lombardia, 20077 Milan, Italy. Hauptthemen laut MEDLINE: Hepatitis C, Hepacivirus. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Hepatitis C virus (HCV) infection is a significant public health problem affecting 58 million people worldwide, including 3.9 million in Europe. Many of these infections go undiagnosed because chronic infection is often asymptomatic. This observational cohort study presents a detailed examination of hepatitis C virus epidemiology in Lombardia (Italy) and was conducted within the ASST “Melegnano e della Martesana”. The study involved comprehensive HCV screening of 3290 patients accessing the collection points and/or hospitalized in the facilities of the ASST from 20 May 2022 to 13 April 2023. Screening was conducted using serological assays. The prevalence of anti-HCV-positive patients (HCV-Ab) and then HCV-positive patients (RNA) was calculated. Chi-square tests examined the associations between continuous and categorical variables. Logistic regression was used to evaluate the influence of demographic and geographic variables as predictors of HCV positivity. The study revealed an overall HCV-Ab prevalence of 0.912% (CI (0.59–1.24%)) in the examined cohort, of whom 15.15% (two females and three males) were positive for HCV RNA. The prevalence of HCV RNA positivity was 0.152% (CI (0.05–0.35%)). Sex disparity was evident, with male patients exhibiting a higher prevalence compared to females, confirmed by logistic regression (0.0147 vs. 0.0061–OR = 2.44; CI (0.0059–0.0124)). Age stratification indicated an ascending trend in prevalence with age, peaking at 1.35% in individuals aged over 50. These findings underscore the critical need for targeted HCV screening, contributing valuable insights to the global epidemiology of HCV in the era of DAAs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Azienda Socio-Sanitaria Territoriale Melegnano Martesana, Regione Lombardia, 20077 Milan, Italy.
- Multidisciplinary Department of Medical-Surgical and Dental Specialties, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy.
- IRCCS San Raffaele Hospital, Vita-Salute University, 20132 Milan, Italy.
- Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy.
ORCID-Profile: Dario Di Stasio, Alberta Lucchese, Daniele Gentili, Carlo Signorelli, Dorina Lauritano
Zitieren
APA
Nardone, M., Di Stasio, D., Lucchese, A., Gentili, D., Cattabianchi, G., Signorelli, C., Sarchi, P., Pulcrano, G., Lembo, V., Pirola, P. M., Lauritano, D., & Carinci, F. (2024). Hepatitis C Epidemiology: Insights from a Comprehensive Cohort Study in ASST Melegnano and Martesana, Lombardia Region, Northern Italy. Pathogens. https://doi.org/10.3390/pathogens13030215
Vancouver
Nardone M, Di Stasio D, Lucchese A, Gentili D, Cattabianchi G, Signorelli C, et al. Hepatitis C Epidemiology: Insights from a Comprehensive Cohort Study in ASST Melegnano and Martesana, Lombardia Region, Northern Italy. Pathogens. 2024. doi:10.3390/pathogens13030215
BibTeX
@article{Nardone2024,
author = {Nardone, Michele and Di Stasio, Dario and Lucchese, Alberta and Gentili, Daniele and Cattabianchi, Giulia and Signorelli, Carlo and Sarchi, Pierangelo and Pulcrano, Giovanna and Lembo, Valentino and Pirola, Paola Maria and Lauritano, Dorina and Carinci, Francesco},
title = {Hepatitis C Epidemiology: Insights from a Comprehensive Cohort Study in ASST Melegnano and Martesana, Lombardia Region, Northern Italy},
journal = {Pathogens},
year = {2024},
doi = {10.3390/pathogens13030215}
}
EUVIMED